Patents by Inventor Sami Nazzal

Sami Nazzal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10855450
    Abstract: There is provided a physical layer security (PLS) system for enhanced cryptographic security and diversity of transmitted data, the system comprising a transmitter for first, converting the data into a plurality of OFDM symbols; second, multiplexing the plurality of OFDM symbols into parallel M OFDM streams; and third, performing spatial interleaving (SI) on the parallel M OFDM streams using a secret key. The system further comprises a receiver for receiving and de-scrambling the transmitted plurality of data samples, wherein software-defined radio (SDR) units are used as the system transmitter and receiver.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: December 1, 2020
    Assignee: DUBAI ELECTRONIC SECURITY CENTER
    Inventors: Husameldin Hussain Adam Mukhtar, Arafat Al-Dweik, Tasnim Bassam Sami Nazzal, Hussain Al-Ahmad, Wathiq Mansoor
  • Publication number: 20200354562
    Abstract: The present invention includes compositions and methods of making films, adhesive patches, or composites comprising a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG) and a partially hydrophilic oil, wherein the composition transitions from a viscous liquid, to an adhesive, and to a film as a weight percent (wt %) ratio of PCL-PVAc-PEG to partially hydrophilic oil changes.
    Type: Application
    Filed: January 31, 2019
    Publication date: November 12, 2020
    Inventor: Sami Nazzal
  • Patent number: 8790723
    Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: July 29, 2014
    Assignee: Jarrow Formulas, Inc.
    Inventors: Mansoor A Khan, Sami Nazzal
  • Publication number: 20120269792
    Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).
    Type: Application
    Filed: March 28, 2012
    Publication date: October 25, 2012
    Applicant: JARROW FORMULAS, INC.
    Inventors: Mansoor A. Khan, Sami Nazzal
  • Patent number: 8158162
    Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: April 17, 2012
    Assignee: Jarrow Formulas, Inc.
    Inventors: Mansoor A. Khan, Sami Nazzal
  • Publication number: 20100166873
    Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).
    Type: Application
    Filed: June 29, 2009
    Publication date: July 1, 2010
    Inventors: Mansoor A. Khan, Sami Nazzal
  • Patent number: 7588786
    Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug or nutraceutical or dietary supplement. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: September 15, 2009
    Assignee: Jarrow Formulas, Inc.
    Inventors: Mansoor A. Khan, Sami Nazzal
  • Publication number: 20030147927
    Abstract: A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).
    Type: Application
    Filed: November 14, 2002
    Publication date: August 7, 2003
    Inventors: Mansoor A. Khan, Sami Nazzal